GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Equity Group AS (OCSE:PEG) » Definitions » 10-Year RORE %

Pharma Equity Group AS (OCSE:PEG) 10-Year RORE % : -0.32% (As of Dec. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Pharma Equity Group AS 10-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Pharma Equity Group AS's 10-Year RORE % for the quarter that ended in Dec. 2024 was -0.32%.

The industry rank for Pharma Equity Group AS's 10-Year RORE % or its related term are showing as below:

OCSE:PEG's 10-Year RORE % is ranked better than
65.55% of 595 companies
in the Biotechnology industry
Industry Median: -6.61 vs OCSE:PEG: -0.32

Pharma Equity Group AS 10-Year RORE % Historical Data

The historical data trend for Pharma Equity Group AS's 10-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma Equity Group AS 10-Year RORE % Chart

Pharma Equity Group AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
10-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.25 - -66.14 -4.10 -0.32

Pharma Equity Group AS Quarterly Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
10-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.10 -2.73 -2.25 -2.30 -0.32

Competitive Comparison of Pharma Equity Group AS's 10-Year RORE %

For the Biotechnology subindustry, Pharma Equity Group AS's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharma Equity Group AS's 10-Year RORE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Equity Group AS's 10-Year RORE % distribution charts can be found below:

* The bar in red indicates where Pharma Equity Group AS's 10-Year RORE % falls into.


;
;

Pharma Equity Group AS 10-Year RORE % Calculation

Pharma Equity Group AS's 10-Year RORE % for the quarter that ended in Dec. 2024 is calculated as:

10-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 10-year -Cumulative Dividends per Share for 10-year )
=( -0.03--0.445 )/( -128.245-0 )
=0.415/-128.245
=-0.32 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2024 and 10-year before.


Pharma Equity Group AS  (OCSE:PEG) 10-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Pharma Equity Group AS 10-Year RORE % Related Terms

Thank you for viewing the detailed overview of Pharma Equity Group AS's 10-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharma Equity Group AS Business Description

Traded in Other Exchanges
N/A
Address
Slotsmarken 18, 2.th., Horsholm, DNK, DK-2970
Pharma Equity Group AS is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develop technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement. Its drug candidates include RNX-011, RNX-021, RNX-022, RNX-023, RNX-041, and RNX-051 .